A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
- Conditions
- Venous Leg UlcerDiabetic Foot Ulcer
- Registration Number
- NCT06453187
- Lead Sponsor
- Integra LifeSciences Corporation
- Brief Summary
The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of hard-to-heal diabetic foot and venous leg ulcers.
- Detailed Description
Hard to heal Chronic wounds affect a significant percentage of patients over their lifetime. For example, diabetic foot ulcers (DFU) are a major health complication that affect up to 15% of individuals with diabetes mellitus over their lifetime. The treatment of hard to heal chronic wounds is extremely challenging as ulcers such as DFUs and Venous Leg Ulcers (VLUs) may not respond to standard of care (SC) treatment and frequently become infected.
Advanced wound products like CAMPs have become an important strategy in the treatment of hard-to-heal chronic wounds by trapping and binding the patients' own cells to rebuild the dermis layer of the skin to aid in healing.
The study will evaluate the clinical utility of Multiple CAMPs in the closure of hard to heal diabetic foot ulcers and venous leg ulcers in subjects in comparison to Standard of Care treatment.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 350
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percentage of complete wound closure for target ulcer 1-12 weeks The percentage of target ulcers, DFU and VLU, achieving complete wound closure Complete wound closure is defined as 100% re-epithelialization of the ulcer surface without detectable exudate
- Secondary Outcome Measures
Name Time Method Time to complete wound closure for target ulcer 1-12 weeks Time to closure will be determined for each treatment group and compared to SOC
Percentage of wound area reduction for target ulcer 1-12 weeks Percent Area Reduction (PAR) will be calculated from measurements at Week 1 compared to measurements at week 12
Adverse Events 1-14 weeks Incidence of adverse events will be evaluated weekly from the first study visit to the Closure Confirmation Visit (CCV).
Changes to pain associated with the target ulcer 1-14 weeks Change in target ulcer pain assessed weekly from the first study visit to the Closure Confirmation Visit (CCV), using a 0 to 10 Pain scale with 0 = "No Pain" and 10 = "Most Intense Pain Imaginable".
Determine improvement in Quality of Life 1-14 weeks Quality of Life assessed at the study randomization visit and the Closure Confirmation Visit (CCV), using a Minimal Important Difference (MID) of 0.50 based on the averaged overall score from 0 to 4 of all items the Wound Quality of Life (wQOL) checklist, with higher score indicating worse wQOL
Improvement of the Forgotten Wound Score (FWS) 1-14 weeks Forgotten Wound Score (FWS) assessed at the study randomization visit and the Closure Confirmation Visit (CCV) based a 0 to 100 scale with higher indicating a high degree of "forgetting" the wound
Trial Locations
- Locations (12)
Center for Clinical Research
🇺🇸San Francisco, California, United States
Medstar Washington Hospital Center (MWHC)
🇺🇸Washington D.C., District of Columbia, United States
Barry University Clinical Research
🇺🇸Tamarac, Florida, United States
Comprehensive Wound Healing Center, Northwell Health
🇺🇸Lake Success, New York, United States
Phase One Clinical Trials, Inc.
🇺🇸Bakersfield, California, United States
Angel City Research
🇺🇸Los Angeles, California, United States
Symphony Research
🇺🇸Jacksonville, Florida, United States
Denali Health Plant City, LLC
🇺🇸Plant City, Florida, United States
Health Goods Management, LLC
🇺🇸Winter Park, Florida, United States
Midwest Foot and Ankle Clinics
🇺🇸Hoffman Estates, Illinois, United States
Scroll for more (2 remaining)Center for Clinical Research🇺🇸San Francisco, California, United StatesMaria PeraltaContact800-363-1069maria@ccr-trials.comReyzelman Alexander, DPMPrincipal Investigator